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8Abstract
Background: Neuroﬁlament proteins (Nf) are highly speciﬁc biomark-
ers for neuronal death and axonal degeneration. As these markers
become more widely used, an inter–laboratory validation study is re-
quired to identify assay criteria for high quality performance.
Methods: The UmanDiagnostics NF–light ® enzyme–linked im-
munoabsorbant assays (ELISA) for the neuroﬁlament light chain (NfL,
68 kDa) was used to test the intra–assay and inter-laboratory coef-
ﬁcient of variation (CV) between 35 laboratories world–wide on 15
cerebrospinal ﬂuid (CSF) samples. Critical factors, such as sample
transport and storage, analytical delays, reaction temperature and
time, the laboratories’ accuracy and preparation of standards were
documented and used for the statistical analyses.
Results: The intra–laboratory CV averaged 3.3% and the inter–
laboratory CV 59%. The results from the test laboratories correlated
with those from the reference laboratory (R=0.60, p<0.0001). Cor-
recting for critical factors improved the strength of the correlation. Dif-
ferences in the accuracy of standard preparation was identiﬁed as the
most critical factor. Correcting for the error introduced by variation in
the protein standards improved the correlation to R=0.98, p<0.0001
with an averaged inter–laboratory CV of 14%. The corrected overall
inter–rater agreement was subtantial (0.6) according to Fleiss’ multi–
rater kappa and Gwet’s AC1 statistics.
Conclusion: This multi–center validation study identiﬁed the lack
of preparation of accurate and consistent protein standards as the
main reason for a poor inter–laboratory CV. This issue is also rele-
vant to other protein biomarkers based on this type of assay and will
need to be solved in order to achieve an acceptable level of analytical
accuracy. The raw data of this study is available online.
keywords: neuroﬁlament, NfL, NF-L, NEFL, biomarker, validation
91 Introduction
Protein biomarkers are relevant for diagnostics and prognosis and they are
increasingly used as inclusion criteria and as a secondary outcome mea-
sure for treatment trials. With the availability of high–throughput proteomic
methods large numbers of potential protein biomarkers have been discov-
ered. However, surprisingly few withstand the test of time and bridge the
bench to bedside gap. Two examples within the ﬁeld of neurodegener-
ative diseases are the tau and amyloid–beta1−42 proteins. Both proteins
were found to be key components in the pathology of Alzheimer’s disease.
Several assays were developed, of which the enzyme–linked immunoab-
sorbant assays (ELISA) were employed routinely. Evidence emerged that
cerebrospinal ﬂuid (CSF) tau and amyloid–beta1−42 levels could be good
diagnostic tests for Alzheimer’s disease [1, 2] and new diagnostic criteria
including CSF tau and amyloid–beta1−42 levels were proposed [3]. Dis-
appointingly, repeated validation studies of CSF tau and amyloid–beta1−42
levels demonstrated an unacceptable inter–laboratory coefﬁcient of vari-
ation (CV) of up to 53% [4, 5, 6]. The factors inﬂuencing the CV remain
largely unknown.
The present study was designed to measure the quantitative inﬂuence
of a number of controllable parameters in a multicenter study involving
35 laboratories worldwide. The rationale was to control for parameters
inherent to shipment and handling of test material and related to different
laboratory procedures in order to optimize the inter–laboratory CV.
The biomarker chosen for analysis was the neuroﬁlament light protein
(NfL) [7, 8]. Neuroﬁlaments are heteropolymers composed of at least four
subunit proteins: α–internexin/Nf66 and the triplet of the neuroﬁlament
light, medium (NfM) and heavy chain (NfH) [9, 10]. Neuroﬁlament pro-
teins are the most reliable protein biomarker validated for quantiﬁcation of
neurodegeneration [10, 11]. Their emerging importance for basic science,
clinical trials and laboratory practice cannot be overestimated.
2 Materials and methods
2.1 Kits and equipment
The NF-L kits were obtained from UmanDiagnostics, Umea, Sweden. The
kit is a sandwich ELISA with two highly speciﬁc NF-L monoclonal antibod-
ies and no cross-reactivity with other known brain antigens [12, 13, 14].
10Large thermometers, allowing easy visualisation of the temperature
(Table 1), were purchased from the Lab Warehouse (TG835-15). All ther-
mometers were calibrated in London prior to shipment.
2.2 CSF samples
Fifteen CSF samples (50 mL each sample, collected from patients who un-
derwent extraventricular drainage for management of acute hydrocephalus)
were collected in polypropylene tubes and immediately centrifuged (5000
rpm for 5 minutes). Supernatants were aliquotted and stored at -80◦C in
1.5–2.0 mL Eppendorf tubes until analysis. In agreement with the Ethic
Committee and the United Kingdom Human Tissue Act, all patient details
were anonymised.
2.3 Analytical procedures
The ELISA (UmanDiagnostics NF-light ®) was performed as previously
described [13]. In brief, each laboratory reconstituted each of the freeze–
dried NfL standards (puriﬁed bovine spinal cord with a purity >98%) with
240µL of sample diluent in a 1.5 mL Eppendorf vial to give a concentration
of 40 ng/mL79. The vial was gently mixed until the standard was completely
solubilized and then left to stand at room temperature (RT) for 10 minutes.
A series of eight Eppendorf vials was prepared, with the ﬁrst vial containing
900 µL of sample diluent and vials 2 to 8, 600 µL of sample diluent. Each
laboratory then added 300 µL of the lyophilized standard to the ﬁrst vial
to give a concentration of 10 µg/L. A doubling dilution using 600 µL in
each step was performed and vial 8 was left only with sample diluent to
give the blank reading (0 ng/mL NfL). The concentration for vials 1 to 7 is
summarised in Table 3.
The freeze–dried ELISA plates were washed with 3 x 5–minute cy-
cles with washing solution (300 µL). Next, 100 µL of standards and sam-
ples were added in quadruplicate (= 4 measurements) and incubated for
1 hour at RT at 800 rpm agitation on a shaker. After another three 5–
minute wash cycles 100µL of the biotin–labeled anti–NfL monoclonal an-
tibody were added to each well. The plate was incubated for 45 minutes
(RT, 800 rpm agitation). Following another wash cycle (3 x 5 minutes), 100
µL of streptavidin–HRP conjugate were added to each well. The plate was
incubated for 30 minutes (RT, 800 rpm). A last wash cycle (3 x 5 minutes)
79The volume of stock solution for the two freeze–dried NfL standards amounts to 480
µL
11was performed and 100 µL of 3,3’,5,5’-tetramethylbenzidine (TMB) were
added to each well. After incubating the plate for 15 minutes (RT) the
color reaction was stopped with 50 µL of stop solution (0.18 M H2SO4).
The absorbance (optical density, OD) of each well was read at 450 nm
(test) and 700 nm (blank).
All laboratories performed only one run.
2.4 Data analysis and strategy for validation
The raw data was sent to London (AP) for analysis and to Amsterdam (CT)
for independent control. The concentration of the NfL samples was calcu-
lated based on each laboratory’s standard curve using the closest three
ODs of the quadruplicates. The results were then discussed with each lab-
oratory. One dataset was again sent to Amsterdam (CT) for independent
control. Results from samples which gave a higher OD than the highest
standard were excluded as this study did not allow for extrapolation. All
raw data were then subjected to statistical analysis.
SAS software (version 9.2, SAS Institute, Inc., Cary, North Carolina,
USA) was used for all statistical analyses and graphs. Data was presented
as median and interquartile range (IQR). The coefﬁcient of variation (CV)
was calculated for each measurement as the standard–deviation divided
by the mean. The result was then multiplied by 100 for expression as
a percentage. Correlation analyses were performed using Pearson’s R
for normally distributed and Spearman’s R for non–Gaussian data. Partial
correlation analyses were performed on predeﬁned variables: temperature
at which the ELISA was performed, time of the colorimetric reaction, time
delay between shipment and analysis of samples, accuracy of each labo-
ratory in respect to preparation of standards and intra–assay CV. The data
for each sample was ranked in order to analyse the inter–laboratory agree-
ment. The inter–laboratory agreement was assessed using kappa statis-
tics for multiple raters and multiple samples [15] and rated as described
[16]. The Fleiss’ multiple rater kappa was calculated on those samples
successfully measured by each laboratory using the SAS magree macro
(version 1.2). The conditional kappa for each response category as well
as the overall agreement are presented. In addition, kappa coefﬁcients
were also calculated using the more robust AC1 statistics introduced by
Gwet [17] using the SAS inter rater macro (version 1.0, downloaded from
http://www.stataxis.com/ﬁles/sas/INTER RATER.TXT).
123 Results
The samples were shipped on dry ice and arrived in perfect frozen stor-
age conditions in 34 (97%) of the laboratories (Table 1). In one case the
samples were delayed at an airport for 2 days and arrived defrosted (lab-
oratory #26). Samples were stored at -80◦C by 33 of the laboratories until
analysis. The average delay from shipment of samples to analyses was
two weeks (Table 1). All laboratories used yellow top (100-200 µL) pipettes
for pipetting samples and standards into the ELISA plate. These pipettes
were speciﬁcally calibrated prior to the experiment by 51% of laboratories.
In all other cases pipettes were calibrated on a routine basis as part of
normal laboratory practice. For the preparation of standards 83% of labo-
ratories used a different set of pipettes, which were able to handle larger
volumes (up to 1000 µL).
The ELISA kit worked successfully in 33/35 (94%) of the participating
laboratories. In two laboratories, the ELISA did not work due to very low
optical densities (OD <0.01) in one, probably reﬂecting a pipetting error
due to mismatch of antibodies. Almost uniformly high ODs were found
by another laboratory (#14), probably reﬂecting cross-contamination. The
temperature at which the ELISA was performed averaged 25◦C (Table 1).
The time given for the colorimetric reaction averaged 14 minutes (median
15 minutes).
In nine laboratories the standard curve went into saturation. In these
cases the top standard and a samples with a high NfL concentration (sam-
ples #1, #5, #6, #9, #10, #13 and #14, Figure 1) had to be excluded. In
this study it was not allowed to extrapolate and therefore we were unable
to calculate the concentration of a sample which fell outside the range of
the standard curve. For this reason the NfL concentration could not be cal-
culated from the optical density of 203/801 (26.5%) of all samples (Table
2). The failure rate was highest for sample #5 (33/2, 94.3%). In contrast,
the NfL concentration could be calculated from the results of all labora-
tories for sample #4 (35/35, 100%, Figure 1). Table 2 summarises the
success rate for determining the OD for each sample and the failure rate
for calculating the absolute concentration. The percentage agreement for
the ranking of samples was higher if the ranking was based on OD instead
of protein concentration for 6 samples (#3, #7, #8, #10, #11, #12). The
agreement between laboratories for individual samples ranged from fair
(sample #2) to almost perfect (sample #4, Table 2). The overall agreement
was substantial [16] using either Fleiss’ multi–rater kappa (overall kappa
0.602, p<0.0001) or Gwet’s AC1 statistics (overall conditional AC1 0.595,
13standard error 0.081, p<0.0001; unconditional AC1 0.595, standard error
0.084, p<0.0001.).
The overal ranking of the absolute protein concentration was identical
to what was found for the OD (Table 2). But only for one sample (#4)
a result was obtained from all laboratories, preventing calculation of the
inter–laboratory agreement using kappa statistics.
3.1 Intra–laboratory assay CV
The average intra–laboratory assay CV was 3.3% (median 2.7%). The
breakdown for each standard and sample is summarised in Figure 2. The
intra-assay CV was best for high concentrations of NfL (standard 1: 10,000
ng/mL) and worst for low concentrations of NfL (standard 8: 0 ng/mL).
3.2 Inter–laboratory assay CV
The concentration of NfL was calculated based on each laboratory’s stan-
dard curve. Figure 1 shows that there was a large discrepancy in the
reported values between the laboratories. This translated to an average
inter–laboratory assay CV of 59% (median 47%, Figure 3).
3.3 Validation parameters
This validation study was designed to assess the inﬂuence of quantiﬁable
parameters on the inter–laboratory assay CV. The values of all laboratories
were compared to those from the reference laboratory (London). Using all
CSF samples, there was a weak correlation of the absolute NfL concen-
tration of R=0.60 (p<0.0001).
Temperature The partial correlation analysis demonstrated the inﬂuence
of the temperature at which the assay was performed with R decreasing
to 0.58 (p<0.0001).
Time Also the time of color development had little inﬂuence on the re-
sults. Correcting for this variable in the partial correlation analysis, R in-
creased marginally to 0.62 (p<0.0001).
Delay in analysis The time delay between sending out the samples and
analysis had no effect on the results (R=0.60, p<0.0001).
14Laboratory accuracy as estimated by the intra–assay CV The intra–
assay CV (accuracy of each laboratory) had no effect (R=0.60, p<0.0001).
Preparation of standards The greatest inﬂuence on inter–laboratory
validation was found to be variation in the concentration of the standards
used by each laboratory to calculate the CSF NfL concentration of the
samples. This is illustrated by two laboratories which analyzed the sam-
ples only two days apart at almost equal temperature (26◦C and 27◦C,
Table 3). The two standard curves are not parallel and contain different
concentrations of NfL. Surprisingly the optical densities for the CSF sam-
ples are almost identical (0–2% difference, Table 3). However, the reported
concentration of CSF NfL differed considerably: 43–53% (Table 3).
It is possible that a non–systematic error was introduced because 84%
of the laboratories used different pipettes to prepare the standards and
pipette the samples (Table 1). In order to analyse the potential error
introduced by differences in the concentration of the NfL standard, the
CSF samples were normalized separately to the highest optical density for
each laboratory (a one point callibration to a top value of 1). Comparing
these normalised ODs, the correlation of the results improved to R=0.72
(p<0.0001).
Figure 1 shows that not all laboratories measured the highest value for
the same sample and the inter–laboratory rater agreement was not per-
fect for all samples (Table 2). In order to standardise we selected one
sample in which the protein concentration was available from most of the
participating laboratories. In addition, this sample had a sufﬁcient high
protein concentration to allow for normalisation of the remaining samples.
We did therefore chose to normalise for sample 7 (82% success rate for
protein concentration, Table 2). Sample 7 had an average NfL concentra-
tion higher then in six other samples (#2, #3, #4, #8, #11, #12) with suf-
ﬁcient success rates to allow for a correlation analysis.Standardizing the
normalization procedure to CSF sample 7 further improved the correlation
to R=0.98 (p<0.0001, Figure 4).
3.4 Optimised inter–laboratory assay CV
Optimising the results to the largest effect found (standardisation to CSF
sample 7), due to a non–systematic error in preparation of protein stan-
dards, reduced the inter–laboratory assay CV to an average of 14%. Again,
a better CV was found for CSF samples with a high NfL protein concentra-
tion (Figure 5).
154 Discussion
This validation study identiﬁed parameters inﬂuencing the inter–laboratory
CV. In descending importance these were the preparation of the standard
curve, time of the colorimetric reaction, delay between shipment and sam-
ple analysis, intra–laboratory CV, and temperature during the experiment.
The importance of identifying these factors is highlighted by the strength
of the correlation between the results from the test and reference labora-
tories. For uncontrolled conditions there was only a weak correlation with
R=0.60 with an inter–laboratory CV of 64.8%. Under controlled conditions
this was improved to a correlation of R=0.98 with an inter–laboratory CV
of 14%. Under optimal conditions an inter–laboratory CV of less than 15%
should be achievable.
The most important ﬁnding of this study is the inﬂuence of the prepara-
tion of the standards. Controlling for all other parameters, this can account
for a two–fold difference in reported values. This variation is in part ex-
plained by limited accuracy of the pipettes. Only half of the laboratories
calibrated their pipettes prior to the experiment. The other half calibrated
their pipettes on a regular basis, which is generally regarded as good labo-
ratory practice. A limitation of our study design is that this information was
self–reported and could therefore be a source of unaccounted variation.
One peculiarity of NfL is that it can self–assemble [18, 19, 20, 21]. Thus
the formation of aggregates is a possibility. Aggregates can be dissolved
either with time or using sonication. A difference in the solubilisation of
the lyophilized NfL reference probably accounts for a large part of dis-
crepancies between laboratories. We suspect that differences between
laboratories in the preparation of the standards is also the likely cause of
the unacceptable high inter–laboratory CV in other studies [4, 5, 6]. At
present this key factor is not controlled for by any of the available ELISA
kits for protein biomarkers. It is important to note that the inter–rater relia-
bility is typically measured when all raters (e.g. laboratories) operate under
similar conditions. Therefore the identiﬁcation of a new extragenous factor
has two implications. Firstly, the statistical strength of the kappa coefﬁcient
is limited. Secondly, a future controlled experiment should be conducted to
evaluate the effect of standard preparation on the agreement coefﬁcient.
All enzymes work within a range of temperature. The enzyme used in
this experiment was horseradish peroxidase (HRP). The colorimetric reac-
tion depends on the oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) and
is optimal around 25◦C at pH 7.0. All experiments were performed under
ideal thermal conditions and correcting for temperature did not improve the
16results.
The enzyme activity is calculated as moles of substrate converted per
time unit. Because the time kinetics for HRP are not completely linear,
variation in reaction time can inﬂuence the outcome of the experiment,
particularly if the reaction reaches saturation. In this study saturation was
reached for a number of samples. As our partial correlation analysis shows
correcting for time did only have a very small effect on the data.
The delay between shipment of samples and analysis is important for
protein biomarkers, which have a limited stability. NfL has been found to
be stable at -80◦C 10 years after sampling [22]. Consistent with this data
a delay in time from shipment to analysis was not statistically relevant.
There are substantial limitations to this study. Firstly, it was not possible
to control for all extragenous factors. We have summarised all extragenous
factors collected in form of a table. Secondly, the effect of the now identi-
ﬁed relevance of standard prepartion has not been tested prospectively in
a controlled experiment. We intend to address this issue in a future study.
Thirdly, a number of observations have been self–reported (e.g. calliba-
ration of pipettes). Because the participating laboratories are located in
different countries and the limited experimental time, it will remain chal-
lenging to collect this information by one single observer. Fourth, to keep
this manuscript focused and transparent limited use of statistical analyses
was considered necessary. The raw data of our study has therefore been
made available online. We are keen to hear about alternative statistical
approaches to this complex issue, particularly in dealing with missing rat-
ings which will remain a problem for this type of reliability studies. Many
of the present statistical analyses were correlative. It needs to be borne in
mind that a statistical correlation does not proof causality.
This large validation study on an ELISA for a protein biomarker demon-
strated that the experience and accuracy (intra–assay CV) of each labo-
ratory had only a minor inﬂuence on the outcome. This is reassuring,
meaning that any laboratory should be in the position to use the ELISA,
but will need to establish in–house reference ranges. In a post–hoc analy-
sis the correlation analysis on the absolute concentration of CSF NfL levels
between two laboratories experienced in the development of this type of
ELISA (London and G¨ otheborg), yielded an R of 0.99 (p<0.0001). Our
conclusion from this result is that at present any treatment trial including
NfL as a protein biomarker may beneﬁt from batch analyses in one labo-
ratory to ensure the highest degree of accuracy. The low intra–laboratory
CV is encouraging in this respect. Alternatively, the use of an internal
laboratory quality control (such as sample 7 in this study), is strongly rec-
ommended. This study is consistent with previous data showing that hu-
17man factors are an important factor adding to inaccuracy [23]. Our results
therefore highlight the importance of a careful adherence to the analyti-
cal procedure. The routine application of this ELISA will require carefull
training of staff including calibration procedures in order to minimise the
intra–laboratory inter–assay CV.
In summary this validation study on an ELISA for the quantiﬁcation
of NfL from human CSF revealed difﬁculties, due to the preparation of
accurate and consistent standards. Even though an unacceptable poor
inter–laboratory assay CV is known also for other proteins, such as tau
and amyloid–beta1−42 [4, 5, 6], this is not yet controlled for. Under optimal
conditions an inter–laboratory CV of 14% should be achievable for this NfL
ELISA.
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20Table 1: Factors recorded for assay validation. The median (IQR), number
and percentage are shown.
Factor Description
Number of participants n=35
Sample condition on arrival (◦C) -80 (n=34), 20 (n=1)
Sample storage prior to analyses (◦C) -80 (n=33), -40 (n=1), -20 (n=1)
ELISA kit storage prior to analyses (◦C) 4 (n=33), 20 (n=2)
Delay to start of analysis (days) 14 (8–30)
Pipettes calibrated prior to experiment (18) 51%
100-200µL (yellow top) pipettes used for samples 100%
Different pipettes used for preparing standards 84%
Temperature at which ELISA was performed 25.3 (24.0-26.5)
Time of colour reaction (minutes) 15 (12–15)
21Table 2: Success rates for measuring the OD and calculating the absolute NfL
protein concentration for each sample. The overall rank (1= lowest rank, 9=highest
rank) of a sample is shown alongside the percentage of laboratories who ranked
the sample equally (% of labs). One laboratory (#14) measured only one sample
and was therefore not included into this analysis. The ranking was not calculated for
ODs which were not measured by all of the 34 remaining laboratories. Fleiss’ kappa
and Gwet’s AC1 statistics were calculated on the ranked OD. The conditional kappa
for each response category is shown as well as the overall agreement (there was
no difference between Gwet’s conditional and unconditional AC1 statistics for this
data, therefore only one column is presented.). Fleiss’ kappa and Gwet’s AC1 could
not be calculated on the protein concentration due to a less then 100% success rate
in 8 of 9 ranked samples. Not available = —
Sample OD . NfL [ng/mL]
number Success Rank % of labs Kappa AC1 Success Rank % of labs
#1 34/34 (100%) 9 72% 0.47 0.46 23/34 (68%) 9 77%
#2 34/34 (100%) 6 65% 0.38 0.36 29/34 (85%) 6 65%
#3 34/34 (100%) 3 68% 0.47 0.45 33/34 (97%) 3 63%
#4 34/34 (100%) 1 100% 1.00 1.00 34/34 (100%) 1 100%
#5 26/34 (77%) — — — — 2/34 (6%) — —
#6 32/34 (94%) — — — — 14/34 (41%) — —
#7 34/34 (100%) 7 87% 0.79 0.79 28/34 (82%) 7 77%
#8 34/34 (100%) 4 94% 0.87 0.87 30/34 (88%) 4 89%
#9 26/34 (77%) — — — — 5/34 (15%) — —
#10 34/34 (100%) 8 74% 0.53 0.52 25/34 (74%) 8 67%
#11 34/34 (100%) 5 62% 0.42 0.41 29/34 (85%) 5 56%
#12 34/34 (100%) 2 68% 0.47 0.46 32/34 (94%) 2 66%
#13 29/34 (85%) — — — — 7/34 (21%) — —
#14 31/34 (91%) — — — — 11/34 (32%) — —
#15 33/34 (97%) — — — — 25/34 (74%) — —
Overall — — — 0.60 0.60 — — —
22Table 3: Preparation of standards was identiﬁed as the most important pa-
rameter inﬂuencing the inter–laboratory CV. In this example the raw data
from two laboratories closely matched for other parameters (temperature
27◦C and 26◦C, days between shipment and analysis 30 and 28 days, time
of color reaction 15 and 8 minutes, respectively) are shown. Surprisingly,
the optical densities for the CSF samples from these two laboratories are
almost identical (0—2% difference). For the standards the OD varies over a
wider range (4–35% difference). This is the reason for the large difference
in the reported results of CSF NfL concentrations (43 to 53%). The con-
centration for the NfL standards was deﬁned as described in the analytical
procedure. Note that for laboratory #26 the mean OD of sample 1 (2.94)
was higher than the mean OD for the highest standard (2.79). Because we
did not allow for extrapolation in this study this sample would not have been
included in the analyses.
Specimen Mean OD Difference NfL (ng/mL) Difference
Lab #26 Lab #18 OD (%) Lab #26 Lab #18 NfL (%)
Standard 1 2.79 3.12 11% 10 10 —
Standard 2 1.89 2.92 35% 5 5 —
Standard 3 1.22 1.72 29% 2.5 2.5 —
Standard 4 0.66 0.92 18% 1.25 1.25 —
Standard 5 0.40 0.47 15% 0.625 0.625 —
Standard 6 0.23 0.22 4% 0.313 0.313 —
Standard 7 0.14 0.11 11% 0.156 0.156 —
Sample 1 2.94 2.96 1% 10.899 5.075 53%
Sample 7 2.35 2.31 2% 7.394 3.675 51%
Sample 11 1.74 1.74 0% 4.484 2.574 43%
23Figure 1: The concentration of CSF NfL levels (µg/mL) measured per sam-
ple is shown. Individual data points are represented by dots, the box–and–
whisker boxes indicate the median and interquartile (25–75%) range.
24Figure 2: Intra–assay CV. The bar–chart shows the intra–assay CV for all
standards and samples analyzed. The intra–assay CV averages to 4.0%
(small horizontal bars).
25Figure 3: Inter–laboratory assay CV. The bar–chart shows the inter–
laboratory assay CV for each individual sample. The averaged inter–
laboratory assay CV is 64.8%.
26Figure 4: Correlation analysis on standardized normalization of the optical
density to CSF sample #7 (R=0.98, p<0.0001).
27Figure 5: The optimized inter–laboratory CV, based on the normalized
mean OD of the CSF samples as a series is shown. All CSF samples (#2,
#3, #4, #8, #11, #12) were normalized to CSF sample #7. The optimized
inter–laboratory CV averages 13.8% (median 12%).
28